Agios Pharmaceuticals’ Tibsovo (ivosidenib) Receives Approval For R/R Acute Myeloid Leukemia (AML) and IDH1 Mutation

 Agios Pharmaceuticals’ Tibsovo (ivosidenib) Receives Approval For R/R Acute Myeloid Leukemia (AML) and IDH1 Mutation

Agios Pharmaceuticals’ Tibsovo (ivosidenib) Receives Approval For R/R Acute Myeloid Leukemia (AML) and IDH1 Mutation

Shots:

  • The approval is based on P-I AG120-C-011 (NCT02074839) study results assessing Tibsovo (ivosidenib, 500mg) in 174 patients with r/r AML and IDH1 mutation aged 67 yrs.
  •  P-I AG120-C-011 study results: CR+CRh rate 32.8%; CR rate 24.7%; median CR+CRh 8.2 mos.; median time to best response of CR or CRh 2.0mos.; median duration to exposure 3.9mos.; 41/110 (37.3%) patient became independent from RBC or platelet transfusion; 21/174 (12%) are on stem cell transplantation + Tibsovo treatment
  • Tibsovo (ivosidenib, 500mg) is a novel PO isocitrate dehydrogenase-1 (IDH1) inhibitor targeted for r/r AML with IDH1 mutation

Click here to read full press release/ article | Ref: Agios | Image: The Street

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post